BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16569343)

  • 1. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
    Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
    Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hormone refractory prostate cancer.
    Knox JJ; Moore MJ
    Semin Urol Oncol; 2001 Aug; 19(3):202-11. PubMed ID: 11561988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
    Oh WK; Tay MH; Huang J
    Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
    Petrylak D
    BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment of advanced prostate cancer.
    Ismail M; Gomella LG
    Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapeutic approaches for hormone-refractory prostate cancer.
    Stavridi F; Karapanagiotou EM; Syrigos KN
    Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy in advanced prostate cancer.
    Beedassy A; Cardi G
    Semin Oncol; 1999 Aug; 26(4):428-38. PubMed ID: 10482185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic approach to hormone-refractory prostate cancer.
    Saad F; Al Dejmah A; Perrotte P; McCormack M; Bénard F; Valiquette L; Karakiewicz PI
    Can J Urol; 2006 Apr; 13 Suppl 2():52-6. PubMed ID: 16672130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
    Berry WR
    Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
    Petrioli R; Fiaschi AI; Francini E; Pascucci A; Francini G
    Cancer Treat Rev; 2008 Dec; 34(8):710-8. PubMed ID: 18620815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of chemotherapy in prostate cancer. Minireview.
    Odrázka K; Vanásek J; Vaculíková M; Stejskal J; Filip S
    Neoplasma; 2000; 47(4):197-203. PubMed ID: 11043822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for non-hormone refractory prostate cancer.
    Winquist E
    Can J Urol; 2006 Feb; 13 Suppl 1():67-70. PubMed ID: 16526986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?".
    Ryan CJ; Eisenberger M
    J Clin Oncol; 2005 Nov; 23(32):8242-6. PubMed ID: 16278479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxetaxel: new indication. Prostate cancer: a few more weeks.
    Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.